|
1
|
McCormick B, Winter K, Hudis C, Kuerer HM,
Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, et
al: RTOG 9804: A prospective randomized trial for good-risk ductal
carcinoma in situ comparing radiotherapy with observation. J Clin
Oncol. 33:709–715. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Corben AD: Pathology of invasive breast
disease. Surg Clin North Am. 93:363–392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duraker N, Hot S, Akan A and Nayir PO: A
comparison of the clinicopathological features, metastasis sites
and survival outcomes of invasive lobular, invasive ductal and
mixed invasive ductal and lobular breast carcinoma. Eur J Breast
Health. 16:22–31. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cho KR and Shih IM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chan JK, Cheung MK, Husain A, Teng NN,
West D, Whittemore AS, Berek JS and Osann K: Patterns and progress
in ovarian cancer over 14 years. Obstet Gynecol. 108((3 Pt 1)):
521–528. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jacinto FV and Esteller M: Mutator
pathways unleashed by epigenetic silencing in human cancer.
Mutagenesis. 22:247–253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Futreal PA, Liu Q, Shattuck-Eidens D,
Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A,
Swensen J and Miki Y: BRCA1 mutations in primary breast and ovarian
carcinomas. Science. 266:120–122. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Birgisdottir V, Stefansson OA,
Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG and Eyfjord JE:
Epigenetic silencing and deletion of the BRCA1 gene in sporadic
breast cancer. Breast Cancer Res. 8:R382006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esteller M, Silva JM, Dominguez G, Bonilla
F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky
EA, et al: Promoter hypermethylation and BRCA1 inactivation in
sporadic breast and ovarian tumors. J Natl Cancer Inst. 92:564–569.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Butcher DT and Rodenhiser DI: Epigenetic
inactivation of BRCA1 is associated with aberrant expression of
CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast
tumours. Eur J Cancer. 43:210–219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sudbø J, Reith A and Lingjaerde OC:
Gene-expression profiles in hereditary breast cancer. N Engl J Med.
344:20292001.PubMed/NCBI
|
|
12
|
Veer LJ, Dai H, van de Vijver MJ, He YD,
Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen
AT, et al: Gene expression profiling predicts clinical outcome of
breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sahnane N, Carnevali I, Formenti G,
Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A,
Rizzo F, et al: BRCA methylation testing identifies a subset of
ovarian carcinomas without germline variants that can benefit from
PARP inhibitor. Int J Mol Sci. 21:97082020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX
and Wan XP: Epigenetic inactivation of BRCA1 through promoter
hypermethylation in ovarian cancer progression. J Obstet Gynaecol
Res. 39:549–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Snell C, Krypuy M, Wong EM; kConFab
investigators, ; Loughrey MB and Dobrovic A: BRCA1 promoter
methylation in peripheral blood DNA of mutation negative familial
breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer
Res. 10:R122008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Al-Moghrabi N, Al-Qasem AJ and Aboussekhra
A: Methylation-related mutations in the BRCA1 promoter in
peripheral blood cells from cancer-free women. Int J Oncol.
39:129–135. 2011.PubMed/NCBI
|
|
17
|
Wong EM, Southey MC, Fox SB, Brown MA,
Dowty JG, Jenkins MA, Giles GG, Hopper JL and Dobrovic A:
Constitutional methylation of the BRCA1 promoter is specifically
associated with BRCA1 mutation-associated pathology in early-onset
breast cancer. Cancer Prev Res (Phila). 4:23–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Prajzendanc K, Domagala P, Hybiak J, Rys
J, Huzarski T, Szwiec M, Tomiczek-Szwiec J, Redelbach W, Sejda A,
Gronwald J, et al: BRCA1 promoter methylation in peripheral blood
is associated with the risk of triple-negative breast cancer. Int J
Cancer. 146:1293–1298. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gupta S, Jaworska-Bieniek K, Narod SA,
Lubinski J, Wojdacz TK and Jakubowska A: Methylation of the BRCA1
promoter in peripheral blood DNA is associated with triple-negative
and medullary breast cancer. Breast Cancer Res Treat. 148:615–622.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y
and Noguchi S: BRCA1 promoter methylation in peripheral blood cells
is associated with increased risk of breast cancer with BRCA1
promoter methylation. Breast Cancer Res Treat. 129:69–77. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Al-Moghrabi N, Nofel A, Al-Yousef N,
Madkhali S, Amer SM, Alaiya A, Shinwari Z, Al-Tweigeri T, Karakas
B, Tulbah A and Aboussekhra A: The molecular significance of
methylated BRCA1 promoter in white blood cells of cancer-free
females. BMC Cancer. 14:8302014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lønning PE, Berge EO, Bjørnslett M,
Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F,
Bjørneklett S, Eriksen C, et al: White blood cell BRCA1 promoter
methylation status and ovarian cancer risk. Ann Intern Med.
168:326–334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jung Y, Hur S, Liu J, Lee S, Kang BS, Kim
M and Choi YJ: Peripheral blood BRCA1 methylation profiling to
predict familial ovarian cancer. J Gynecol Oncol. 32:e232021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Al-Moghrabi N, Al-Showimi M, Al-Yousef N,
Al-Shahrani B, Karakas B, Alghofaili L, Almubarak H, Madkhali S and
Al Humaidan H: Methylation of BRCA1 and MGMT genes in white blood
cells are transmitted from mothers to daughters. Clin Epigenetics.
10:992018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bosviel R, Garcia S, Lavediaux G, Michard
E, Dravers M, Kwiatkowski F, Bignon YJ and Bernard-Gallon DJ: BRCA1
promoter methylation in peripheral blood DNA was identified in
sporadic breast cancer and controls. Cancer Epidemiol.
36:e177–e182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tomasetti M, Gaetani S, Monaco F, Neuzil J
and Santarelli L: Epigenetic regulation of miRNA expression in
malignant mesothelioma: MiRNAs as biomarkers of early diagnosis and
therapy. Front Oncol. 9:12932019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tavazoie SF, Alarcon C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massague J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meister J and Schmidt MHH: MiR-126 and
miR-126*: New players in cancer. ScientificWorldJournal.
10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bockmeyer CL, Christgen M, Müller M,
Fischer S, Ahrens P, Länger F, Kreipe H and Lehmann U: MicroRNA
profiles of healthy basal and luminal mammary epithelial cells are
distinct and reflected in different breast cancer subtypes. Breast
Cancer Res Treat. 130:735–745. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang F, Zheng Z, Guo J and Ding X:
Correlation and quantitation of microRNA aberrant expression in
tissues and sera from patients with breast tumor. Gynecol Oncol.
119:586–593. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Qin X, Jiang J and Zhao W:
MicroRNA-126 exerts antitumor functions in ovarian cancer by
targeting EGFL7 and affecting epithelial-to-mesenchymal transition
and ERK/MAPK signaling pathway. Oncol Lett. 20:1327–1335. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pan C, Stevic I, Muller V, Ni Q,
Oliveira-Ferrer L, Pantel K and Schwarzenbach H: Exosomal microRNAs
as tumor markers in epithelial ovarian cancer. Mol Oncol.
12:1935–1948. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wyman SK, Parkin RK, Mitchell PS, Fritz
BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS and
Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as
determined by next generation sequencing of small RNA cDNA
libraries. PLoS One. 4:e53112009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Azzollini J, Pesenti C, Pizzamiglio S,
Fontana L, Guarino C, Peissel B, Plebani M, Tabano S, Sirchia SM,
Colapietro P, et al: Constitutive BRCA1 promoter hypermethylation
can be a predisposing event in isolated early-onset breast cancer.
Cancers (Basel). 11:582019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nakai K, Hung MC and Yamaguchi H: A
perspective on anti-EGFR therapies targeting triple-negative breast
cancer. Am J Cancer Res. 6:1609–1623. 2016.PubMed/NCBI
|
|
38
|
Zhang Y, Wang X, Xu B, Wang B, Wang Z,
Liang Y, Zhou J, Hu J and Jiang B: Epigenetic silencing of miR-126
contributes to tumor invasion and angiogenesis in colorectal
cancer. Oncol Rep. 30:1976–1984. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Volinia S, Bertagnolo V, Grassilli S,
Brugnoli F, Manfrini M, Galasso M, Scatena C, Mazzanti CM, Lessi F,
Naccarato G, et al: Levels of miR-126 and miR-218 are elevated in
ductal carcinoma in situ (DCIS) and inhibit malignant potential of
DCIS derived cells. Oncotarget. 9:23543–23553. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiang Y, Tian Q, Guan L and Niu SS: The
dual role of miR-186 in cancers: Oncomir battling with tumor
suppressor miRNA. Front Oncol. 10:2332020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Orgueira AM: Hidden among the crowd:
Differential DNA methylation-expression correlations in cancer
occur at important oncogenic pathways. Front Genet.
6:1632015.PubMed/NCBI
|
|
42
|
Andersen M, Grauslund M, Ravn J, Sorensen
JB, Andersen CB and Santoni-Rugiu E: Diagnostic potential of
miR-126, miR-143, miR-145, and miR-652 in malignant pleural
mesothelioma. J Mol Diagn. 16:418–430. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yan J, Ma S, Zhang Y, Yin C, Zhou X and
Zhang G: Potential role of microRNA-126 in the diagnosis of
cancers: A systematic review and meta-analysis. Medicine
(Baltimore). 95:e46442016. View Article : Google Scholar : PubMed/NCBI
|
